Drugs of Abuse: Screening and Confirmation Protocols

Drugs-of-abuse testing in forensic, clinical and workplace settings runs as a strict two-tier pipeline. The first tier is a fast, cheap, very sensitive immunoassayscreen. The second tier is a slow, specific, mass-spectrometric confirmation. The reasoning is identical to the presumptive-versus-confirmatory logic used across forensic chemistry disciplines.

Screen first because the lab has to triage hundreds of samples a day. A urine immunoassay gives a yes / no answer in minutes against a class cut-off (for example, 500 ng/mL for amphetamines), which lets the lab discard all true negatives without using expensive instrument time. Confirm second because immunoassays are class-specific, not analyte-specific: an opiate screen does not tell you whether the morphine came from poppy seeds, codeine, prescription pethidine or heroin (via the 6-MAM metabolite). Confirmation by GC-MSor LC-MS-MS gives the molecular identity with a retention time plus a fragment ion pattern that survives cross-examination.

The cardinal rule for MCQs: a positive screen is not a positive result. Only a confirmed analyte at or above the confirmation cut-off, on a properly collected and chain-of-custody-protected specimen, is reported as positive.

The US SAMHSA workplace panel is the global reference grid that most forensic and clinical laboratories adapt for their own SOPs, including Indian labs. Cut-offs are expressed in ng/mL urine.

The extended panels add benzodiazepines, barbiturates, methadone (and EDDP metabolite), oxycodone, buprenorphine and fentanyl. Indian National Anti-Doping Agency (NADA) testing through the WADA-accredited National Dope Testing Laboratory (NDTL Delhi) uses the WADA list, which is far broader and includes anabolic steroids, peptide hormones, beta-2 agonists and diuretics; the screen-then-confirm logic is the same.

Two interpretation points are worth noting. First, the opiate screen cut-off of 2000 ng/mL is high precisely to suppress poppy-seed false positives; a 300 ng/mL cut-off was used historically. Second, 6-MAM has a 10 ng/mL cut-off because it is unique to heroin (it is the deacetylation product of diacetylmorphine), so a confirmed 6-MAM finding is essentially diagnostic of heroin use.

The choice of matrix determines what question the test can answer. The windows below are given in rough order of magnitude.

Urine is the standard matrix for the workplace and forensic screen because it is non-invasive, contains parent drug plus metabolites at higher concentrations than blood, and gives a detection window that matches typical investigation lag. The trade-off is its vulnerability to adulteration, which is why every accredited urine collection comes with a specimen-validity panel: specific gravity (normal 1.003 to 1.030), pH (normal 4.5 to 8.0), creatinine (normal greater than 20 mg/dL) and adulterant tests for nitrite, chromate, glutaraldehyde and peroxide.

For chronic-use questions, hair analysisis the standard answer. Drugs deposit in the hair shaft from the bloodstream during keratinisation; cutting the proximal centimetre and analysing each subsequent centimetre gives a month-by-month record of exposure. The Indian forensic application is in child-custody disputes, employer drug-policy cases, and historical poisoning casework. Externally deposited contamination is a defence attack, so labs follow a standardised wash protocol before extraction.

All screening immunoassays use the same antibody-against-drug principle but differ in label, format and instrumentation.

EMIT (Enzyme-Multiplied Immunoassay Technique). Drug in the sample competes with drug labelled to glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding. Antibody-bound conjugate is enzymatically inactive; free conjugate oxidises NAD to NADH and is measured at 340 nm. Homogeneous (no separation step), runs on any clinical chemistry analyser, and is the workhorse of Indian SFSL drug screens.

CEDIA (Cloned Enzyme Donor Immunoassay). Two genetically engineered inactive fragments of beta-galactosidase reassemble into the active enzyme; drug bound to the enzyme-donor fragment can be blocked from reassembly by antibody. Free drug in the sample frees the enzyme-donor fragment, restoring activity. Used for benzodiazepines and methadone.

FPIA (Fluorescence Polarization Immunoassay). Fluorescein-drug conjugate rotates fast and depolarises light when free; rotation slows when antibody-bound, so polarisation rises. Inverse competition. Now less common because the proprietary instrument has been discontinued, but still tested.

KIMS (Kinetic Interaction of Microparticles in Solution). Drug-coated microparticles aggregate when antibody crosslinks them, increasing turbidity. Free drug in the sample inhibits aggregation. Read at a fixed wavelength on a clinical analyser. Common on Roche cobas platforms.

Lateral-flow rapid kits. Dipstick or cassette immunoassays with antibody-coated capture lines. Drug in the sample blocks the binding of the gold or latex conjugate, so the test line stays clear (positive) and the control line is always coloured (valid). These are the kits Indian state police carry under NDPS Section 41for road-side and crime-scene screening. They are screening tools, never confirmatory.

A key distinction: EMIT, CEDIA, FPIA and KIMS are all homogeneous (no separation step); lateral-flow uses physical capture but no analyte-specific wash step.

Confirmation is done by GC-MSfor volatile, thermally stable analytes and by LC-MS-MS for polar, thermolabile or large molecules. The practical rule: if the analyte carries hydroxyl, carboxyl or amine groups (opiates, amphetamines, THC-COOH), GC-MS requires derivatisation; LC-MS-MS does not.

GC-MS with derivatisation. The polar functional groups are masked with silyl, acyl or alkyl groups to improve volatility and chromatographic peak shape.

• BSTFA (N,O-bis(trimethylsilyl)trifluoroacetamide) plus TMCS catalyst for opiates (morphine, codeine, 6-MAM): adds trimethylsilyl groups to hydroxyls.
• HFBA (heptafluorobutyric anhydride) for amphetamines and methamphetamine: adds heptafluorobutyryl groups to the secondary amine, also giving an electron-rich fragment that is easy to track in selected-ion monitoring.
• MSTFA, MTBSTFA, BSA and other silyl reagents for THC-COOH and steroids in NADA / WADA doping work.

Detection is in selected-ion monitoring (SIM) for sensitivity, monitoring three diagnostic ions per analyte with fixed retention time and ion-ratio criteria (typically within 20 percent of the calibrator).

LC-MS-MS in MRM mode. No derivatisation needed. The analyte is ionised in ESI or APCI, the precursor ion is selected by Q1, fragmented in q2 collision cell, and one or two product ions are selected by Q3. Each analyte is identified by retention time, precursor mass, two product ions and the product-ion ratio. Quantification is against a deuterated internal standard (for example morphine-d3, cocaine-d3) added before extraction. LC-MS-MS is now the dominant confirmation platform for benzodiazepines, fentanyl, novel psychoactive substances and the WADA panel.

Both platforms produce reports that survive court because the identification rests on two orthogonal dimensions (retention time and mass spectrum) at a documented concentration above the confirmation cut-off.

Donor adulteration is the single biggest practical problem in workplace and pre-employment urine testing.

• Dilution. Drinking water or substituting tap water. Detected by low specific gravity (less than 1.003) and low creatinine (less than 20 mg/dL).
• pH adulterants. Vinegar (low pH) or ammonia / bleach (high pH). Detected by out-of-range pH (less than 4.5 or greater than 8.0).
• Oxidising adulterants. Nitrite, chromate, pyridinium chlorochromate, hydrogen peroxide. These destroy THC-COOH and morphine on the immunoassay strip. Detected by specific colour reagents on specimen-validity panels.
• Glutaraldehyde. Sold under brand names (UrineLuck and others) to denature antibodies; detected by aldehyde-specific colorimetric reagents (such as carbonyl indicators or test strips that change from rose to purple).
• Visine eye-drops. Benzalkonium chloride masks cannabinoid antibody binding. Detected indirectly through bulk-matrix anomalies.
• Niacin / vinegar / cranberry juice myths. Folk methods, largely ineffective at the SAMHSA cut-offs but still attempted.

Indian DFSS toxicology SOP requires the specimen-validity panel to be reported alongside the drug result. A positive screen on an invalid specimen is reported as "specimen rejected" rather than positive, because the chain of attack in court is too clean otherwise.

The Indian legal frame for drugs-of-abuse casework is the NDPS Act 1985 read with NCB Standing Order 1/88 (sampling) and 1/89 (procedures for seizure, sampling and dispatch). The sampling SOP requires the seizing officer to draw two representative samples of 5 g (small quantity) or 24 g (commercial) from each homogeneous lot, seal them in cloth-and-paper packets with the case-property seal, prepare Form NCB-1 (test memo), and dispatch one sample to the relevant CFSL or state DFSS within 72 hours under a sealed-cover chain of custody. The second sample is the court sample and is opened only if a re-test is ordered.

Routing depends on the analyte and the seizing agency. NCB seizures go to CFSL Hyderabad, CFSL Chandigarh or CFSL New Delhi depending on jurisdiction; state police seizures go to the state SFSL drug section. Hospital emergency-room drug-of-abuse screens for poisoning admissions are handled by hospital clinical toxicology labs (AIIMS, PGIMER, JIPMER, NIMHANS) and follow biological matrixhandling rules separate from the NDPS chain.

Sports doping in India sits in a parallel ecosystem. NADA Delhi commissions sample collection through Doping Control Officers; samples are analysed at NDTL Delhi (the only WADA-accredited Indian laboratory). NDTL follows the WADA International Standard for Laboratories with its own A-sample and B-sample architecture, which mirrors the NCB two-sample logic but is procedurally distinct.

NDPS Section 27 (consumption of drugs) carries a maximum sentence of one year (cocaine, morphine, heroin) or six months (other drugs), while trafficking under Sections 21, 22 or 23 attracts ten to twenty years for commercial quantity. The forensic report's quantity figure, together with the seizure weight, is what decides the section the accused is charged under, which is why the drug metaboliteconfirmation and the quantitative GC-MS or LC-MS-MS number are scrutinised in court.